GlassScriptPhysician profile
Wen Cai
NPI 1083902563
$12,353.78
in general payments reported to CMS, 2019-2025
29 companies · $2,397 in 2025
The $2,397 reported for 2025 was more than what 96% of Acute Care (Nurse Practitioner) providers received nationally (typical 2025 total: $151).
See the full distribution for Acute Care (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,220 · 2022: $4,319 · 2023: $2,061 · 2024: $2,357 · 2025: $2,397.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,815.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,815.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,320.09 | 2021-2025 | |
| Celgene Corporation | $1,620.69 | 2021-2024 | Zeposia |
| E.R. Squibb & Sons, L.L.C. | $1,248.10 | 2021-2023 | Zeposia |
| Janssen Biotech, INC. | $1,068.57 | 2021-2025 | Tremfya, Stelara, Simponi Aria |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $910.24 | 2021-2025 | Xifaxan, Relistor, Trulance |
| Takeda Pharmaceuticals U.S.A., INC. | $857.54 | 2022-2025 | Entyvio, Gattex, Eohilia |
| Janssen Scientific Affairs, LLC | $397.62 | 2021-2024 | Tremfya, Stelara |
| Regeneron Healthcare Solutions, INC. | $331.70 | 2023-2025 | Dupixent |
| Gilead Sciences, INC. | $319.67 | 2021-2025 | |
| Intercept Pharmaceuticals, INC. | $273.20 | 2021-2025 | Ocaliva |
| Madrigal Pharmaceuticals | $269.21 | 2025 | Rezdiffra |
| Pfizer INC. | $233.38 | 2022-2025 | |
| Phathom Pharmaceuticals, INC. | $213.49 | 2024-2025 | Voquezna |
| Genzyme Corporation | $179.42 | 2022-2025 | |
| Boston Scientific Corporation | $176.99 | 2022-2024 | Watchman Access System |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $123.92 | 2024-2025 | Omvoh |
| Braintree Laboratories, INC. | $109.46 | 2021-2025 | Suflave |
| Ardelyx, INC. | $109.06 | 2023-2025 | Ibsrela |
| Merck Sharp & Dohme LLC | $96.25 | 2023-2024 | Dificid |
| Qol Medical, LLC | $87.35 | 2022-2025 | Sucraid |
| Ironwood Pharmaceuticals, INC | $85.74 | 2023-2024 | Linzess |
| Amgen INC. | $80.70 | 2022-2023 | Avsola, Amjevita |
| Organon LLC | $73.87 | 2024-2025 | Hadlima, Renflexis |
| Ferring Pharmaceuticals INC. | $50.79 | 2022-2025 | Rebyota |
| Aimmune Therapeutics, INC. | $31.47 | 2024 | |
| Fresenius Kabi USA, LLC | $24.01 | 2024 | Idacio |
| Daiichi Sankyo INC. | $22.67 | 2022 | |
| Axsome Therapeutics, INC. | $20.21 | 2024 | Auvelity |
| Novo Nordisk INC | $18.37 | 2025 | Wegovy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Wen Cai listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.